

Madhu Kailash Natarajan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/656474/publications.pdf>

Version: 2024-02-01

49
papers

1,480
citations

430442

18
h-index

329751

37
g-index

50
all docs

50
docs citations

50
times ranked

2687
citing authors

#	ARTICLE	IF	CITATIONS
1	A machine learning-based clinical decision support algorithm for reducing unnecessary coronary angiograms. <i>Cardiovascular Digital Health Journal</i> , 2022, 3, 21-30.	0.5	6
2	Remote ECG monitoring to reduce complications following transcatheter aortic valve implantations: the Redirect TAVI study. <i>Europace</i> , 2022, 24, 1475-1483.	0.7	5
3	Before the door: Comparing factors affecting symptom onset to first medical contact for STEMI patients between a high and low-middle income country. <i>IJC Heart and Vasculature</i> , 2022, 39, 100978.	0.6	3
4	Length of initial prescription at hospital discharge and long-term medication adherence for elderly, post-myocardial infarction patients: a population-based interrupted time series study. <i>BMC Medicine</i> , 2022, 20, .	2.3	1
5	One-Year Costs Associated with Hospitalizations Due to Aortic Stenosis in Canada. <i>CJC Open</i> , 2021, 3, 82-90.	0.7	1
6	Association of Thrombus Aspiration With Time and Mortality Among Patients With ST-Segment Elevation Myocardial Infarction. <i>JAMA Network Open</i> , 2021, 4, e213505.	2.8	4
7	Rate of COVID-19 infection in patients with ST-segment elevation myocardial infarction. <i>CJC Open</i> , 2021, 3, 1214-1216.	0.7	0
8	Antithrombotic Therapy After Percutaneous Coronary Intervention in Patients with Atrial Fibrillation: Findings from the CONNECT AF+PCI study. <i>CJC Open</i> , 2021, 3, 1419-1427.	0.7	1
9	Complete Revascularization in Patients Undergoing a Pharmacoinvasive Strategy for ST-Segment Elevation Myocardial Infarction: Insights From the COMPLETE Trial. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e010458.	1.4	2
10	Upstream anticoagulation for patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: Insights from the TOTAL trial. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 519-525.	0.7	5
11	Early Observations During the COVID-19 Pandemic in Cardiac Catheterization Procedures for ST-Elevation Myocardial Infarction Across Ontario. <i>CJC Open</i> , 2020, 2, 678-683.	0.7	11
12	Association Between Adherence to Fractional Flow Reserve Treatment Thresholds and Major Adverse Cardiac Events in Patients With Coronary Artery Disease. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 2406.	3.8	30
13	Comparison of Heart Team vs Interventional Cardiologist Recommendations for the Treatment of Patients With Multivessel Coronary Artery Disease. <i>JAMA Network Open</i> , 2020, 3, e2012749.	2.8	15
14	The Use of Decision Modelling to Inform Timely Policy Decisions on Cardiac Resource Capacity During the COVID-19 Pandemic. <i>Canadian Journal of Cardiology</i> , 2020, 36, 1308-1312.	0.8	19
15	Interventions supporting long term adherence and decreasing cardiovascular events after myocardial infarction (ISLAND): pragmatic randomised controlled trial. <i>BMJ, The</i> , 2020, 369, m1731.	3.0	38
16	Remote Ambulatory Cardiac Monitoring Before and After Transcatheter Aortic Valve Replacement. <i>CJC Open</i> , 2020, 2, 416-419.	0.7	10
17	Precautions and Procedures for Coronary and Structural Cardiac Interventions During the COVID-19 Pandemic: Guidance from Canadian Association of Interventional Cardiology. <i>Canadian Journal of Cardiology</i> , 2020, 36, 780-783.	0.8	61
18	Length of Initial Prescription at Hospital Discharge and Long-Term Medication Adherence for Elderly, Post-Myocardial Infarction Patients: Protocol for an Interrupted Time Series Study. <i>JMIR Research Protocols</i> , 2020, 9, e18981.	0.5	5

#	ARTICLE	IF	CITATIONS
19	Antithrombotic Management After Transcatheter Aortic Valve Replacement: A Survey of Canadian Physicians. <i>Canadian Journal of Cardiology</i> , 2019, 35, 1596-1599.	0.8	6
20	The Vancouver 3M (Multidisciplinary, Multimodality, But Minimalist) Clinical Pathway Facilitates Safe Next-Day Discharge Home at Low-, Medium-, and High-Volume Transfemoral Transcatheter Aortic Valve Replacement Centers. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 459-469.	1.1	179
21	Timing of Staged Nonculprit Artery Revascularization in Patients With ST-Segment Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2713-2723.	1.2	88
22	Polygenic Contribution in Individuals With Early-Onset Coronary Artery Disease. <i>Circulation Genomic and Precision Medicine</i> , 2018, 11, e001849.	1.6	41
23	Does Early Coronary Angiography Improve Survival After out-of-Hospital Cardiac Arrest? A Systematic Review With Meta-Analysis. <i>Canadian Journal of Cardiology</i> , 2018, 34, 180-194.	0.8	29
24	Barriers to the use of emergency medical services for ST-elevation myocardial infarction: Determining why many patients opt for self-transport. <i>Journal of Evaluation in Clinical Practice</i> , 2018, 24, 375-379.	0.9	1
25	Factors associated with door-in to door-out delays among ST-segment elevation myocardial infarction (STEMI) patients transferred for primary percutaneous coronary intervention: a population-based cohort study in Ontario, Canada. <i>BMC Cardiovascular Disorders</i> , 2018, 18, 204.	0.7	11
26	Identifying determinants of medication adherence following myocardial infarction using the Theoretical Domains Framework and the Health Action Process Approach. <i>Psychology and Health</i> , 2017, 32, 1176-1194.	1.2	40
27	Structural Heart Disease Intervention: The Canadian Landscape. <i>Canadian Journal of Cardiology</i> , 2017, 33, 1197-1200.	0.8	5
28	MitraClip and Transcatheter Aortic Valve Replacement in a Patient With Recurrent Heart Failure. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	1.4	2
29	Double-Dose Versus Standard-Dose Clopidogrel According to Smoking Status Among Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	9
30	Negotiating Tensions Between Theory and Design in the Development of Mailings for People Recovering From Acute Coronary Syndrome. <i>JMIR Human Factors</i> , 2017, 4, e6.	1.0	22
31	Optical Coherence Tomography-Guided Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, e003414.	1.4	37
32	Impact of Center Experience on Patient Radiation Exposure During Transradial Coronary Angiography and Percutaneous Intervention: A Patient-Level, International, Collaborative, Multi-Center Analysis. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	19
33	Vascular access and antiplatelet therapies: does one influence the other?. <i>European Heart Journal</i> , 2016, 37, 1131-1132.	1.0	2
34	Outcomes after thrombus aspiration for ST elevation myocardial infarction: 1-year follow-up of the prospective randomised TOTAL trial. <i>Lancet, The</i> , 2016, 387, 127-135.	6.3	187
35	Cluster randomized controlled trial of Delayed Educational Reminders for Long-term Medication Adherence in ST-Elevation Myocardial Infarction (DERLA-STEMI). <i>American Heart Journal</i> , 2015, 170, 903-913.	1.2	36
36	Adherence to process of care quality indicators after percutaneous coronary intervention in Ontario, Canada: a retrospective observational cohort study. <i>Open Heart</i> , 2015, 2, e000200.	0.9	6

#	ARTICLE	IF	CITATIONS
37	Effects of withdrawing vs continuing renin-angiotensin blockers on incidence of acute kidney injury in patients with renal insufficiency undergoing cardiac catheterization: Results from the Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker and Contrast Induced Nephropathy in Patients Receiving Cardiac Catheterization (CAPTAIN) trial. <i>American Heart Journal</i> , 2015, 170, 110-116.	1.2	70
38	Comparison of Dual-antiplatelet Therapy to Mono-antiplatelet Therapy After Transcatheter Aortic Valve Implantation: Systematic Review and Meta-analysis. <i>Canadian Journal of Cardiology</i> , 2015, 31, 775-784.	0.8	38
39	Providing optimal regional care for ST-segment elevation myocardial infarction: a prospective cohort study of patients in the Hamilton Niagara Haldimand Brant Local Health Integration Network. <i>CMAJ Open</i> , 2015, 3, E1-E7.	1.1	11
40	Increased Uptake of Guideline-Recommended Oral Antiplatelet Therapy: Insights from the Canadian Acute Coronary Syndrome Reflective. <i>Canadian Journal of Cardiology</i> , 2014, 30, 1725-1731.	0.8	26
41	Advanced chronic kidney disease in patients undergoing transcatheter aortic valve implantation: insights on clinical outcomes and prognostic markers from a large cohort of patients. <i>European Heart Journal</i> , 2014, 35, 2685-2696.	1.0	130
42	Delayed educational reminders for long-term medication adherence in ST-elevation myocardial infarction (DERLA-STEMI): Protocol for a pragmatic, cluster-randomized controlled trial. <i>Implementation Science</i> , 2012, 7, 54.	2.5	8
43	Need for Permanent Pacemaker as a Complication of Transcatheter Aortic Valve Implantation and Surgical Aortic Valve Replacement in Elderly Patients With Severe Aortic Stenosis and Similar Baseline Electrocardiographic Findings. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 540-551.	1.1	145
44	Randomized trial of insulin versus usual care in reducing restenosis after coronary intervention in patients with diabetes. the STent Restenosis And Metabolism (STREAM) study. <i>Cardiovascular Revascularization Medicine</i> , 2012, 13, 95-100.	0.3	13
45	A randomized pilot study of dalteparin versus unfractionated heparin during percutaneous coronary interventions. <i>American Heart Journal</i> , 2006, 151, 175.e1-175.e6.	1.2	14
46	Impact of routine in-hospital assessment of low-density lipoprotein levels and standardized orders on statin therapy in patients undergoing percutaneous coronary interventions. <i>Journal of Invasive Cardiology</i> , 2005, 17, 518-20.	0.4	6
47	Incidence, predictors, and clinical significance of troponin-I elevation without creatine kinase elevation following percutaneous coronary interventions. <i>American Journal of Cardiology</i> , 2004, 93, 750-753.	0.7	64
48	The risks of waiting for cardiac catheterization: a prospective study. <i>Cmaj</i> , 2002, 167, 1233-40.	0.9	9
49	Evaluation of the role of abciximab (Reopro) as a rescue agent during percutaneous coronary interventions: In-hospital and six-month outcomes. <i>Catheterization and Cardiovascular Interventions</i> , 2000, 51, 138-144.	0.7	9